Lunit

328130.KQ

29.08 USD

-0.22

-0.75%

Overview

Last close

29.08 usd

Market cap

847.72M usd

52 week high

58.23 usd

52 week low

23.39 usd

Target price

34.37 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

16.0768

Price/Book Value

8.3733

Enterprise Value

867.69M usd

EV/Revenue

16.7424

EV/EBITDA

-45.3273

Key financials

Revenue TTM

51.83M usd

Gross Profit TTM

51.83M usd

EBITDA TTM

-47.04M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

305.17M usd

Net debt

29.36M usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations and with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.